ストックスクリーナーアプリを入手
2.77
1.42%
-0.04
前日終値:
$2.81
開ける：
$2.82
24時間の取引高:
49,582
Relative Volume:
0.64
時価総額：
$82.65M
収益：
$709.00K
当期純損益:
$-43.14M
株価収益率:
-0.6101
EPS:
-4.54
ネットキャッシュフロー:
$-20.35M
1週間 パフォーマンス:
-4.15%
1か月 パフォーマンス:
-0.36%
6か月 パフォーマンス:
-5.78%
1年 パフォーマンス:
-3.99%
1日の値動き範囲:
$2.57
$2.82
1週間の範囲:
$2.57
$3.06
52週間の値動き範囲:
$1.922
$4.75
OncoCyte Corporation Stock (OCX) Company Profile
名前
OncoCyte Corporation
セクター
電話
510-775-0515
住所
1010 Atlantic Avenue, Suite 102, Alameda, CA
OCX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OCX
OncoCyte Corporation
|
2.77 | 82.65M | 709.00K | -43.14M | -20.35M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.00 | 115.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.16 | 60.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.47 | 37.56B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.86 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.73 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
OncoCyte Corporation Stock (OCX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-28 | 開始されました | Lake Street | Buy |
| 2022-05-24 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2022-03-14 | ダウングレード | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2022-01-07 | 開始されました | Stephens | Overweight |
| 2022-01-06 | 再開されました | Piper Sandler | Overweight |
| 2021-03-17 | 再開されました | Needham | Buy |
| 2021-01-07 | アップグレード | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-16 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2020-11-30 | 開始されました | BTIG Research | Buy |
| 2020-11-10 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2020-07-30 | 繰り返されました | The Benchmark Company | Speculative Buy |
| 2020-07-01 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2020-06-30 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2020-06-02 | 開始されました | Needham | Buy |
| 2019-02-13 | 開始されました | Piper Jaffray | Overweight |
| 2019-01-29 | アップグレード | Janney | Neutral → Buy |
| 2018-12-19 | 再開されました | Lake Street | Buy |
すべてを表示
OncoCyte Corporation (OCX) 最新ニュース
Needham maintains Buy on OncoCyte, price target at $4.25 By Investing.com - Investing.com Nigeria
OncoCyte Corp (OCX) Q1 2025 Earnings Call Highlights: Strategic Advances in Transplant Testing ... - Yahoo Finance
OncoCyte Corp (OCX) Q1 2025 Earnings Call Highlights: Strategic - GuruFocus
OncoCyte (OCX) Maintains 'Buy' Rating and Price Target by Needha - GuruFocus
Needham maintains Buy on OncoCyte, price target at $4.25 - Investing.com
OncoCyte targets 20 transplant center milestone and upcoming FDA submission while advancing rebranding initiative - MSN
OncoCyte (OCX) Seeks FDA Approval by 2026 - GuruFocus
OncoCyte Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: OncoCyte’s Q1 2025 revenue beats expectations - Investing.com
OncoCyte: Q1 Earnings Snapshot - San Antonio Express-News
OncoCyte Corp (OCX) Q1 2025 Earnings: Revenue Soars to $2.1 Mill - GuruFocus
Oncocyte Reports Q1 2025 Results and Business Progress - The Manila Times
Oncocyte Corp. Reports Q1 2025 Revenue of $2.1 Million and Plans Company Renaming - Nasdaq
Oncocyte Corp SEC 10-Q Report - TradingView
Oncocyte to Release First Quarter 2025 Results on May 12, 2025 - The Manila Times
Oncocyte To Release First Quarter 2025 Results On May 12, 2025 - Barchart.com
Best Momentum Stocks to Buy for May 6th - The Globe and Mail
Geode Capital Management LLC Has $326,000 Stock Position in OncoCyte Co. (NASDAQ:OCX) - Defense World
Oncocyte Provides Positive Update on Clinical Trial Progress | O - GuruFocus
Why Tesla Stock Hit the Brakes Today - The Globe and Mail
AP PHOTOS: US stocks sink after a weak report on the economy - The Globe and Mail
Oncocyte (OCX) Advances Towards Crucial Clinical Trial for Trans - GuruFocus
Oncocyte advances toward clinical trial for transplant test By Investing.com - Investing.com India
Oncocyte advances toward clinical trial for transplant test - Investing.com Australia
Oncocyte Provides Positive Update on Clinical Trial Progress - The Manila Times
Oncocyte Provides Positive Update on Clinical Trial Progress | OCX Stock News - GuruFocus
Oncocyte Provides Positive Update On Clinical Trial ProgresS - marketscreener.com
Leading US Transplant Centers Back Oncocyte's Revolutionary Rejection Test Clinical Trial - Stock Titan
OncoCyte (NASDAQ:OCX) Trading Down 3.1% – Here’s What Happened - Defense World
Oncocyte study links blood test to kidney rejection markers - Investing.com
Economic Uncertainty Weighs on PayPal - The Globe and Mail
Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Val - GuruFocus
Oncocyte (OCX) Unveils Promising Data on Transplant Rejection Te - GuruFocus
Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity | OCX Stock News - GuruFocus
Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity - The Manila Times
Groundbreaking Study: Oncocyte's Transplant Test Shows Unprecedented 13-Year Effectiveness in Rejection Detection - Stock Titan
Trane Technologies (TT) Reports Earnings Tomorrow: What To Expect - The Globe and Mail
Service International (SCI) Reports Q1: Everything You Need To Know Ahead Of Earnings - The Globe and Mail
Press Release Distribution & PR Platform - ACCESS Newswire
Public market insider selling at Metro (MRU) - The Globe and Mail
Oncocyte appoints new independent accounting firm - Investing.com
Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer - The Globe and Mail
BioTime Provides Business Update Including Information on AgeX, OncoCyte and Asterias - MarketScreener
OncoCyte (OCX) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
OncoCyte (NASDAQ:OCX) Coverage Initiated by Analysts at StockNews.com - Defense World
OncoCyte Co. (NASDAQ:OCX) Sees Large Increase in Short Interest - Defense World
Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference - TradingView
Oncocyte Unveils Game-Changing Transplant Diagnostic Technology at Major Healthcare Conference - Stock Titan
Analysts’ Recent Ratings Updates for OncoCyte (OCX) - Defense World
Oncocyte Files Secondary Stock Shelf - MarketScreener
OncoCyte (NASDAQ:OCX) Now Covered by Lake Street Capital - Armenian Reporter
OncoCyte Corporation (OCX) 財務データ
収益
当期純利益
現金流量
EPS
3.01%
大文字化:
|
ボリューム (24 時間):